Relja, Maja and Klepac, Nataša
A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease.
Journal of the Neurological Sciences, 248 (1-2).
ISSN 0022-510X (Print)
The cognitive performance of 55 non-demented idiopathic Parkinson's disease (PD) patients treated with levodopa alone or receiving dopamine agonist pramipexole as add-on therapy to levodopa was evaluated in the present study during 6 months of treatment. Neuropsychological tests were administered two times. In the first assessment to differentiate test sensitive to cognitive changes typical for PD control group was also assessed. After 6 months of treatment PD patients were retested only with tests that differentiate them from control group. Compared to controls PD patients showed inferior performance on Stroop Interference test, Trail Making test, letter fluency and Hooper Visual Organization Test. No statistically significant differences between two groups and first and second neuropsychological assessment were found. Present findings indicate that pramipexole as add-on therapy to levodopa is safe in non-demented PD patients in terms of the effect on cognitive performance.
||Antiparkinson Agents - pharmacology - therapeutic use ; Benzothiazoles - pharmacology - therapeutic use ; Cognition - drug effects ; Parkinson Disease - drug therapy - physiopathology ; Adult ; Aged ; Case-Control Studies ; Female ; Follow-Up Studies ; Humans ; Levodopa - therapeutic use ; Male ; Middle Aged ; Neuropsychological Tests - statistics & numerical data
||Katedra za neurologiju
||19 Mar 2007
||23 Sep 2011 16:09
Actions (login required)
Downloads per month over past year